Molecular sieving of red cell membranes during gradual osmotic hemolysis

Summary Rat red blood corpuscles were held stationary with respect to a continuously flowing solution in either a specially constructed centrifuge or in glass filters. The concentration of the solution was gradually decreased to cause the swelling and subsequent gradual osmotic hemolysis of the cells. The passage of the intracellular molecules —potassium, adenylate kinase, and hemoglobin—across the cell membranes and into the flowing solution was determined as a function of time. Ions and molecules begin passage across the membranes in the order of increasing molecular size. The initial flow of potassium is followed by the initial flows of hemoglobin and adenylate kinase. The flow of hemoglobin has been interpreted as the flows of hemoglobin monomers, dimers, and tetramers such that the time sequence is: potassium; hemoglobin monomer; adenylate kinase/hemoglobin dimer; and finally, hemoglobin tetramer. It is concluded that the stressed cell membrane has molecular sieving properties and that the exclusion limit (effective hole size) increases as a function of time during the initial stages of gradual osmotic hemolysis. The process of gradual osmotic hemolysis is discussed in terms of molecular sieving through stress-induced effective membrane holes. It is suggested that a portion of the membrane protein might form an elastic network which would account for the gradual increase in size and apparent homogeneity of the effective holes.This work was prepared under the auspices of the U.S. Atomic Energy Commission.     

ON THE MECHANISM OF THE INHIBITION OF GROWTH BY XYLULOSE IN CHLOROCOCCUM ECHINOZYGOTUM1,2

We previously established that xylulose inhibits the growth of the green alga Chlorococcum echinozygotum. Utilizing experiments involving exposure of the alga to NaHC¹⁴O₃, it was possible to show by counting the C¹⁴ activity of methanolic extracts of the algal cells that xylulose inhibited CO₂ uptake. Subsequently it was shown that xylulose does not inhibit or otherwise influence the Hill reaction in this alga. Several enzymes related to xylulose metabolism were investigated. It was found that xylulokinase was active in C. echinozygotum while phosphoketolase activity was absent. Transketolase was present but its activity was not notably affected by xylulose. Crude carboxydismutase preparations were found to be inhibited by xylulose and xylulose 5-phosphate. However, as carboxydismutase was purified further, this inhibition was relatively less. When xylulose 1,5-diphosphate was prepared synthetically, this compound was found to be the most effective inhibitor of purified algal carboxydismutase. We conclude that d -xylulose enters the cells of C. echinozygotum where it is converted to d -xylulose 1,5-diphosphate which acts as a competitive inhibitor of carboxydismutase.     

Note on Rashevsky's equation for cellular growth

The equation for growth by intussusception involves the product of the internal concentrations ofn metabolites. This products is shown, in general, to satisfy a certain algebraic equation of then-th degree. Approximate solutions are exhibited for a somewhat wider class of cases than are considered by Rashevsky.     

The kinetics of enzyme inactivation

The course of hydrolysis of β-glycerophosphate catalyzed by a group of different enzyme extracts, both with and without the addition of Mg, with and without preincubation of the enzyme, has been studied and the results discussed on the basis of a mathematical analysis. In all the extracts, it appears that two distinct and independently acting constituent enzymes—or perhaps “principles” of the same enzyme—are present, one acting much more rapidly but also more rapidly inactivated than the other. Storage in the refrigerator changes markedly the behavior of both constituents, though in different ways. There is evidence that in some cases an enzyme is limited in its hydrolytic “capacity” in the sense that after an enzyme molecule has decomposed a definite number of substrate molecules, it thereafter becomes entirely passive. Further, there is evidence, in the case of one extract, that the roles of catalytically more and less active constituents in the absence of Mg are reversed in its presence. Finally, a damped periodicity is found which indicates the presence of two factors of an unknown sort which influence and are influenced by the inactivation of the enzyme.     

A note on the horopter

By assuming the fixity (but not the symmetry) of corresponding points on the two retinae, it is possible to derive the equation of any horopter when one is known. In particular when, as experiment shows, one horopter is linear, then all horopters must be conics. These have the form given by Ogle, but whereas Ogle leaves one parameter undetermined at each fixation, on our assumption the only arbitrary parameter is determined by the position of the linear horopter.     

Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors

As demonstrated in preclinical animal models, the disruption of PI3Kδ expression or its activity leads to a decrease in inflammatory and immune responses. Therefore, inhibition of PI3Kδ may provide an alternative treatment for autoimmune diseases, such as RA, SLE, and respiratory ailments. Herein, we disclose the identification of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors. The lead compound demonstrated efficacy in an in vivo mouse KLH model.     

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate

MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albumin (HSA) DARPin® domains within a single polypeptide chain. While there is first clinical validation of a single-domain DARPin® drug candidate, little is known about DARPin® drug candidates comprising multiple domains. Here, we show that MP0250 can be expressed at 15 g/L in soluble form in E. coli high cell-density fermentation, it is stable in soluble/frozen formulation for 2 years as assessed by reverse phase HPLC, it has picomolar potency in inhibiting VEGF-A and HGF in ELISA and cellular assays, and its domains are simultaneously active as shown by surface plasmon resonance. The inclusion of HSA-binding DARPin® domains leads to a favorable pharmacokinetic profile in mouse and cynomolgus monkey, with terminal half-lives of ～ 30 hours in mouse and ～ 5 days in cynomolgus monkey. MP0250 is thus a highly potent drug candidate that could be particularly useful in oncology. Beyond MP0250, the properties of MP0250 indicate that multi-domain DARPin® proteins can be valuable next-generation drug candidates.